Boenning & Scattergood Initiates Coverage on Array BioPharma (ARRY)
More News related to ARRY
- Array BioPharma to Present at the Piper Jaffray Healthcare Conference
- UBS Upgrades Array BioPharma (ARRY) to Buy
- Array BioPharma (ARRY) Reports Q1 Loss of $0.52, Beats by 3c
- Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2010
- Array BioPharma to Report Financial Results for the First Quarter of Fiscal 2010 on November 2, 2009
More News related to New Coverage
- Bank of America (BAC) $18.8B Convertible Preferred Offering Coming Monday
- BofA (BAC) Gets Unwanted Advice From Unwanted CEO Replacements
- Cramer Tries His Best to Top-Tick Amazon (AMZN), Sets Street High $210 Price Target
- Despite Novartis Denial, UBS Makes A Strong Case That They Should Buy Alcon (ACL)
- A Rough Week for AT&T (T)
Boenning & Scattergood initiates coverage on Array BioPharma (Nasdaq: ARRY) with an Outperform rating. Price target $6.
To see more analyst ratings on ARRY Click Here.
Array BioPharma Inc. (Array) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs.
Related Categories
New CoverageStocks Mentioned
+0.02Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
